Achieve Life Sciences, Inc. (ACHV) stock
ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as QUIT
$6.72+0.34 (+5.33%)
Close on Nov 6, 2026Market cap $691.50MP/E –Yield –
Achieve Life Sciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Achieve Life Sciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$47.02M. For fiscal 2025 it was -$49.47M. The highest annual figure on record is $34.88M in fiscal 2009.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$49.47M | – |
| FY2024 | Dec 31, 2024 | -$29.77M | – |
| FY2023 | Dec 31, 2023 | -$24.48M | – |
| FY2022 | Dec 31, 2022 | -$37.57M | – |
| FY2021 | Dec 31, 2021 | -$29.44M | – |
| FY2020 | Dec 31, 2020 | -$13.47M | – |
| FY2019 | Dec 31, 2019 | -$15.22M | – |
| FY2018 | Dec 31, 2018 | -$10.62M | – |
| FY2017 | Dec 31, 2017 | -$9.11M | – |
| FY2016 | Dec 31, 2016 | -$202.00K | – |
| FY2015 | Dec 31, 2015 | -$350.00K | – |
| FY2014 | Dec 31, 2014 | -$17.31M | – |
| FY2013 | Dec 31, 2013 | -$35.93M | – |
| FY2012 | Dec 31, 2012 | -$43.49M | – |
| FY2011 | Dec 31, 2011 | -$20.26M | – |
| FY2010 | Dec 31, 2010 | -$26.84M | -177.0% |
| FY2009 | Dec 31, 2009 | $34.88M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.92M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.68M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.31M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.20M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.41M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.07M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.89M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.54M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.98M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.87M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.23M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.62M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.46M | -135.7% |
| Q2 FY2017 | Jun 30, 2017 | -$18.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$62.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $15.30M | – |
See a number that looks wrong?